Guidant Accepts J&J’s Offer

It’s finally over. Guidant (GDT) will go with Johnson & Johnson (JNJ) for $71 a share. Both boards still need to approve the deal. I guess the hedge funds aren’t powerful as everyone thought. In the end, all Boston Scientific (BSX) did was make a bad deal cost more money.

Posted by on January 14th, 2006 at 11:05 am


The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment. I or my affiliates may hold positions or other interests in securities mentioned in the Blog, please see my Disclaimer page for my full disclaimer.